[Neuroprotection in glaucoma].
The aim of this research is to describe one of the most frequent ophthalmology disease-glaucoma and to look at their neurodegenerative nature and methods to stop disease. We use neuroprotection in glaucoma from a short time but despite of ethiological reasons neuroprotection seems to be one of the main mechanism to slow their progression. This research is talking about new opinions about neuroprotection in glaucoma and their epidemiology and etiology.
Kuprjanowicz
Leszek
L
Katedra i Klinika Okulistyki Pomorskiej Akademii Medycznej w Szczecinie al. Powstańców Wlkp. 72, 70-111 Szczecin.
Karczewicz
Danuta
D
D015784:Betaxolol / Q000627:therapeutic use; D000068438:Brimonidine Tartrate; D018450:Disease Progression; D005901:Glaucoma / Q000188:drug therapy* / Q000453:epidemiology / Q000209:etiology; D006146:Guanidines / Q000627:therapeutic use; D006801:Humans; D008559:Memantine / Q000627:therapeutic use; D018696:Neuroprotective Agents / Q000627:therapeutic use*; D011810:Quinoxalines / Q000627:therapeutic use; D013449:Sulfonamides / Q000627:therapeutic use; D013876:Thiophenes / Q000627:therapeutic use
D006146:Guanidines; D018696:Neuroprotective Agents; D011810:Quinoxalines; D013449:Sulfonamides; D013876:Thiophenes; D000068438:Brimonidine Tartrate; C062765:dorzolamide; D015784:Betaxolol; C004479:pimagedine; D008559:Memantine